Valentin Brodszky

A prosztatarák gazdasági terhe nagy betegregiszterek alapján. Irodalmi áttekintés

INTRODUCTION Prostate cancer, the most frequent malignant disease in males in Europe, accounts for a great proportion of health expenditures. AIM A systematic review of registry-based studies about the cost-of-illness and related factors of prostate cancer, published in the last 10 years. METHOD A MEDLINE-based literature review was carried out between January 1, 2003 and October 1, 2013. RESULTS Fifteen peer-reviewed articles met the criteria of interest. In developed countries radiotherapy, surgical treatment and hormone therapy account for the greatest per capita costs. In Europe early stage tumours (4-7000 €, 2006), while in the USA metastatic prostate cancer (19 900-25 500

A prosztatarák gazdasági terhe nagy betegregiszterek alapján (The economic burden of prostate cancer. A systematic literature overview of registry-based studies)

, 2004) was associated with highest per capita expenses. In Europe the greatest costs incurred within the initial treatment (6400 €/6 months, 2008), while in the USA within the end-of-life care (depending on age: 62 200-93 400

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of rheumatoid arthritis

, 2010). CONCLUSIONS Despite public health importance of prostate cancer, the cost-of-illness literature from Europe is relatively small.

Psoriasisban szenvedő betegek életminőségének vizsgálata Magyarországon = Assessment of health-related quality of life in psoriasis patients in Hungary

INTRODUCTION Prostate cancer, the most frequent malignant disease in males in Europe, accounts for a great proportion of health expenditures. AIM A systematic review of registry-based studies about the cost-of-illness and related factors of prostate cancer, published in the last 10 years. METHOD A MEDLINE-based literature review was carried out between January 1, 2003 and October 1, 2013. RESULTS Fifteen peer-reviewed articles met the criteria of interest. In developed countries radiotherapy, surgical treatment and hormone therapy account for the greatest per capita costs. In Europe early stage tumours (4-7000 €, 2006), while in the USA metastatic prostate cancer (19 900-25 500

Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists

, 2004) was associated with highest per capita expenses. In Europe the greatest costs incurred within the initial treatment (6400 €/6 months, 2008), while in the USA within the end-of-life care (depending on age: 62 200-93 400

Magyarországi perifériás verőérbetegek életminőség és betegségteher vizsgálatának eredményei | Quality of life and burden of disease in peripheral arterial disease: a study among Hungarian patients

, 2010). CONCLUSIONS Despite public health importance of prostate cancer, the cost-of-illness literature from Europe is relatively small.